Journal of Urban Health

, Volume 84, Issue 1, pp 126–136 | Cite as

Physicians’ Knowledge of and Willingness to Prescribe Naloxone to Reverse Accidental Opiate Overdose: Challenges and Opportunities

  • Leo Beletsky
  • Robin Ruthazer
  • Grace E. Macalino
  • Josiah D. Rich
  • Litjen Tan
  • Scott Burris
Article

Abstract

Naloxone, the standard treatment for heroin overdose, is a safe and effective prescription drug commonly administered by emergency room physicians or first responders acting under standing orders of physicians. High rates of overdose deaths and widely accepted evidence that witnesses of heroin overdose are often unwilling or unable to call 9-1-1 has led to interventions in several US cities and abroad in which drug users are instructed in overdose rescue techniques and provided a “take-home” dose of naloxone. Under current Food and Drug Administration (FDA) regulations, such interventions require physician involvement. As part of a larger study to evaluate the knowledge and attitudes of doctors towards providing drug treatment and harm reduction services to injection drug users (IDUs), we investigated physician knowledge and willingness to prescribe naloxone. Less than one in four of the respondents in our sample reported having heard of naloxone prescription as an intervention to prevent opiate overdose, and the majority reported that they would never consider prescribing the agent and explaining its application to a patient. Factors predicting a favorable attitude towards prescribing naloxone included fewer negative perceptions of IDUs, assigning less importance to peer and community pressure not to treat IDUs, and increased confidence in ability to provide meaningful treatment to IDUs. Our data suggest that steps to promote naloxone distribution programs should include physician education about evidence-based harm minimization schemes, broader support for such initiatives by professional organizations, and policy reform to alleviate medicolegal concerns associated with naloxone prescription. FDA re-classification of naloxone for over-the-counter sales and promotion of nasal-delivery mechanism for this agent should be explored.

Keywords

Evidence-based practice Heroin Injection drug use Naloxone Overdose prevention Physician behavior Physician education 

References

  1. 1.
    Zule W. Risk and reciprocity: HIV and the injection drug user. J Psychoact Drugs. 1992;24:242–249.Google Scholar
  2. 2.
    Sporer KA. Strategies for preventing heroin overdose. BMJ. 2003;326(7386):442–444.PubMedCrossRefGoogle Scholar
  3. 3.
    Darke S, Zador D. Fatal heroin ‘overdose’: a review. Addiction. 1996;91(12):1765–1772.PubMedCrossRefGoogle Scholar
  4. 4.
    Warner-Smith M, Darke S, Lynskey M, Hall W. Heroin overdose: causes and consequences. Addiction. 2001;96(8):1113–1125.PubMedCrossRefGoogle Scholar
  5. 5.
    Warner-Smith M, Darke S, Day C. Morbidity associated with non-fatal heroin overdose. Addiction. 2002;97(8):963–967.PubMedCrossRefGoogle Scholar
  6. 6.
    Hall W, Darke S. Trends in opiate overdose deaths in Australia 1979–1995. Drug Alcohol Depend. 1998;52(1):71–77.PubMedCrossRefGoogle Scholar
  7. 7.
    Darke S, Ross J, Hall W. Overdose among heroin users in Sydney, Australia: I. Prevalence and correlates of non-fatal overdose. Addiction. 1996;91(3):405–411.PubMedCrossRefGoogle Scholar
  8. 8.
    Burris S, Edlin B, Norland J. Legal aspects of providing naloxone to heroin users in the United States. Int J Drug Policy. 2001;12:237–248.CrossRefGoogle Scholar
  9. 9.
    Dettmer K, Saunders B, Strang J. Take home naloxone and the prevention of deaths from opiate overdose: two pilot schemes. BMJ. 2001;322:895–896.PubMedCrossRefGoogle Scholar
  10. 10.
    Seal KH, Downing M, Kral AH, et al. Attitudes about prescribing take-home naloxone to injection drug users for the management of heroin overdose: a survey of street-recruited injectors in the San Francisco Bay area. J Urban Health. June 1. 2003;80(2):291–301.PubMedGoogle Scholar
  11. 11.
    McGregor C, Darke S, Ali R, Christie P. Experience of non-fatal overdose among heroin users in Adelaide, Australia: circumstances and risk perceptions. Addiction. 1998;93(5):701–711.PubMedCrossRefGoogle Scholar
  12. 12.
    Darke S, Hall W. Heroin overdose: research and evidence-based intervention. J Urban Health. 2003;80(2):189–200.PubMedGoogle Scholar
  13. 13.
    Dietze P. Intranasal naloxone is an effective first line treatment for suspected opioid overdose in the prehospital setting. Paper presented at: 15th International Conference on the Reduction of Drug Related Harm; April 24, 2004; Melbourne, Australia.Google Scholar
  14. 14.
    Food, Drug, and Cosmetic Act Sec. 503(b)(1). U.S.C. Vol 21; 1999.Google Scholar
  15. 15.
    Centers for Disease Control and P. Heroin overdose deaths—Multnomah County, Oregon, 1993–1999. MMWR — Morbidity & Mortality Weekly Report. 2000;49(28):633–636.Google Scholar
  16. 16.
    Strang J, Darke S, Hall W, Farrell M, Ali R. Heroin overdose: the case for take-home naloxone. BMJ. 1996;312(7044):1435–1436.PubMedGoogle Scholar
  17. 17.
    Strang J, Powis B, Best D, et al. Preventing opiate overdose fatalities with take-home naloxone: pre-launch study of possible impact and acceptability. Addiction. 1999;94(2):199–204.PubMedCrossRefGoogle Scholar
  18. 18.
    Sporer KA. Acute heroin overdose. Ann Intern Med. 1999;130(7):584–590.PubMedGoogle Scholar
  19. 19.
    Vilke GM, Buchanan J, Dunford JV, Chan TC. Are heroin overdose deaths related to patient release after pre-hospital treatment with naloxone? Prehosp Emerg Care. 1999;3(3):183–186.PubMedCrossRefGoogle Scholar
  20. 20.
    Bigg D. Opiate Overdose Prevention/Intervention Using Take-Home Naloxone. Paper presented at: 131st Annual Meeting of the American Public Health Association; November 18, 2003; San Francisco, California.Google Scholar
  21. 21.
    Fiuty P. Naloxone Prescription to IDUs in New Mexico. Paper presented at: 131st Annual Meeting of the American Public Health Association; November 18, 2003; San Francisco, California.Google Scholar
  22. 22.
    MacGillis A. City Overdose Deaths Fell by 12% Last Year: Ilicit Drug Toll of 261 in ’04 Was Lowest in 5 Years. Baltimore Sun. March 28, 2005;A:1.Google Scholar
  23. 23.
    Seal KH, Thawley R, Gee L, et al. Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. J Urban Health. 2005;82(2):303–311.PubMedGoogle Scholar
  24. 24.
    Sherman SG, Kral AH, Lorvick JA. Epidemiology of opiate overdose and response: a review of overdose prevention naloxone prescription interventions. Paper presented at: New York State Department of Health; April 18, 2005; New York City, New York.Google Scholar
  25. 25.
    Campana M. Overdose Mortality and Naloxone Distribution in Italy. Paper presented at: Preventing Heroin Overdose: Pragmatic Approaches; Jan. 13–14, 2000; Seattle, WA.Google Scholar
  26. 26.
    Finkelstein R, Ramos SE. Manual for Primary Care Providers: Effectively Caring for Active Substance Users. New York, NY: New York Academy of Medicine; 2003.Google Scholar
  27. 27.
    National Center on Addiction and Substance Abuse. Missed opportunity: National survey of primary care physicians and patients on substance abuse. New York, NY: Columbia University; 2000.Google Scholar
  28. 28.
    Ding L, Landon BE, Wilson IB, Wong MD, Shapiro MF, Cleary PD. Predictors and consequences of negative physician attitudes toward HIV-infected injection drug users. Arch Intern Med. 2005;165:618–623.PubMedCrossRefGoogle Scholar
  29. 29.
    Gastfriend DR. Physician substance abuse and recovery: what does it mean for physicians—and everyone else? JAMA. 2005;293(12):1513–1515.PubMedCrossRefGoogle Scholar
  30. 30.
    Heller D, McCoy K, Cunningham C. An invisible barrier to integrating HIV primary care with harm reduction services: philosophical clashes between the harm reduction and medical models. Public Health Rep. 2004;119(1):32–39.PubMedGoogle Scholar
  31. 31.
    Swenson-Britt E, Carrougher G, Martin BW, Brackley M. Project Hope: changing care delivery for the substance abuse patient. Clin Nurse Spec. 2000;14(2):92–100.PubMedCrossRefGoogle Scholar
  32. 32.
    Rich JD, McKenzie M, Macalino GE, et al. A syringe prescription program to prevent infectious disease and improve health of injection drug users. J Urban Health. 2004;81(1):122–134.PubMedGoogle Scholar
  33. 33.
    Coffin PO, Blaney S, Fuller C, Vadnai L, Miller S, Vlahov D. Support for buprenorphine and methadone prescription to heroin-dependent patients among New York City physicians. Am J Drug Alcohol Abuse. 2006;32(1):1–6.PubMedCrossRefGoogle Scholar
  34. 34.
    National Center for Health Statistics. Health, United States, 2003, with Chartbook on Trends in the Health of Americans. Hyattsville, Maryland: U.S. Department of Health and Human Services; 2003.Google Scholar
  35. 35.
    Tobin KE, Gaasch WR, Clarke C, MacKenzie E, Latkin CA. Attitudes of emergency medical service providers toward naloxone distribution programs. J Urban Health. 2005;82(2):296–302.PubMedGoogle Scholar
  36. 36.
    O’Connor PG, Selwyn PA, Schottenfeld RS. Medical progress: medical care for injection-drug users with human immunodeficiency virus infection. New Engl J Med. 1994;331:450–459.PubMedCrossRefGoogle Scholar
  37. 37.
    Wartenberg AA. ‘Into whatever houses I enter’. HIV and injecting drug use. JAMA. 1994;271(2):151–152.PubMedCrossRefGoogle Scholar
  38. 38.
    Weinrich M, Stuart M. Provision of methadone treatment in primary care medical practices: review of the Scottish experience and implications for U.S. Policy. JAMA. 2000;283:1343–1348.PubMedCrossRefGoogle Scholar
  39. 39.
    Kendal EM. Effects of Attitudes on Delivery of Healthcare. The Community Health Nurse and Alcohol Problems. Rockford, Maryland: U.S. Department of Health; 1978.Google Scholar
  40. 40.
    Leshner AI. Science-based views of drug addiction and its treatment. JAMA. 1999;282(14):1314–1316.PubMedCrossRefGoogle Scholar
  41. 41.
    Coffin PO, Fuller C, Vadnai L, Blaney S, Galea S, Vlahov D. Preliminary evidence of health care provider support for naloxone prescription as overdose fatality prevention strategy in New York City. J Urban Health. 2003;80(2):288–290.PubMedGoogle Scholar
  42. 42.
    Limbert C, Lamb R. Doctors’ use of clinical guidelines: two applications of the Theory of Planned Behaviour. Psychol Health Med. 2002;7(3):301–310.CrossRefGoogle Scholar
  43. 43.
    Cundiff GW, Weidner AC, Visco AG, Bump RC, Addison WA. A survey of pessary use by members of the American Urogynecologic Society. Obstet Gynecol. 2000;95(6 Pt 1):931–935.PubMedCrossRefGoogle Scholar
  44. 44.
    Urban N, Anderson GL, Tseng A. Effects on response rates and costs of stamps vs business reply in a mail survey of physicians. J Clin Epidemiol. 1993;46(5):455–459.PubMedCrossRefGoogle Scholar
  45. 45.
    Wolfe JM, Lein DY, Lenkoski K, Smithline HA. Analgesic administration to patients with an acute abdomen: a survey of emergency medicine physicians. Am J Emerg Med. 2000;18(3):250–253.PubMedCrossRefGoogle Scholar
  46. 46.
    Gerbert B, Maguire BT, Bleecker T, Coates TJ, McPhee SJ. Primary care physicians and AIDS. Attitudinal and structural barriers to care. JAMA. 1991;266(20):2837–2842.PubMedCrossRefGoogle Scholar
  47. 47.
    Ritson EB. Alcohol, drugs and stigma. Int J Clin Pract. 1999;53:549–551.PubMedGoogle Scholar
  48. 48.
    Coffin PO, Linas BP, Factor SH, Vlahov D. New York City pharmacists’ attitudes toward sale of needles/syringes to injection drug users before implementation of law expanding syringe access. J Urban Health. 2000;77(4):781–793.PubMedCrossRefGoogle Scholar
  49. 49.
    Rich JD, Whitlock TL, Towe CW, et al. Prescribing syringes to prevent HIV: a survey of infectious disease and addiction medicine physicians in Rhode Island. Subst Use Misuse. 2001;36(5):535–550.PubMedCrossRefGoogle Scholar
  50. 50.
    Hilton BA, Thompson R, Moore-Dempsey L, Janzen RG. Harm reduction theories and strategies for control of human immunodeficiency virus: a review of the literature. J Adv Nurs. 2001;33(3):357–370.PubMedCrossRefGoogle Scholar
  51. 51.
    Wodak A, Cooney A. Effectiveness of sterile needle and syringe programmes. Int J Drug Policy. 2005;16(Supp 1):S31–44.CrossRefGoogle Scholar
  52. 52.
    Klausner JD, Chaw JK. Patient-delivered therapy for chlamydia: putting research into practice. Sex Transm Dis. 2003;30(6):509–511.PubMedCrossRefGoogle Scholar
  53. 53.
    New York State Assembly. An act to amend the public health law, in relation to opioid overdose prevention. McKinney’s Public Health Law. 2005–2006 Regular Sessions ed; 2006.Google Scholar
  54. 54.
    An Act Relating To Drugs; Authorizing And Releasing From Liability Persons Who Administer Opioid Antagonists; Releasing From Liability Licensed Health Care Professionals; Declaring An Emergency. New Mexico Statutes Annotated. Vol §§ 24-31-1 & -2; 2006.Google Scholar

Copyright information

© The New York Academy of Medicine 2006

Authors and Affiliations

  • Leo Beletsky
    • 1
    • 6
  • Robin Ruthazer
    • 2
  • Grace E. Macalino
    • 3
  • Josiah D. Rich
    • 4
  • Litjen Tan
    • 5
  • Scott Burris
    • 1
  1. 1.Temple University Beasley School of LawPhiladelphiaUSA
  2. 2.Biostatistics Research Center, Institute for Clinical Research and Health Policy StudiesTufts-New England Medical CenterBostonUSA
  3. 3.Tufts University School of Medicine, Institute for Clinical Research and Health Policy StudiesTufts New England Medical CenterBostonUSA
  4. 4.Brown University and The Miriam HospitalProvidenceUSA
  5. 5.American Medical AssociationChicagoUSA
  6. 6.Temple University Beasley School of LawPhiladelphiaUSA

Personalised recommendations